Theseus Pharmaceuticals Inc (NAS:THRX)
$ 4.06 0 (0%) Market Cap: 181.28 Mil Enterprise Value: -20.19 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 24/100

Theseus Pharmaceuticals Inc To Host Virtual Investor Event To Review Updated Data Transcript

May 25, 2023 / 09:30PM GMT
Release Date Price: $8.72 (-3.22%)
Operator

Good afternoon, and welcome to Theseus Pharmaceuticals Investor Event. (Operator Instructions)

I would now like to turn the conference over to Brad Dahms, Chief Financial Officer at Theseus. Please proceed.

Bradford D. Dahms
Theseus Pharmaceuticals, Inc. - CFO

Thank you, operator, and good afternoon, everyone. Welcome to Theseus' investor event, where we will discuss initial dose escalation data from our Phase I/II clinical trial of THE-630 for patients with Advanced GIST. This afternoon, we issued a press release outlining these results. The press release and the presentation we will reference during today's event can be found on the Investors and Media section of Theseus's website at theseusrx.com. As a reminder, this call is being recorded and a replay will also be archived on the company's website for 90 days.

At this time, I would like to remind listeners that during this call, we may make forward-looking statements and ask that you refer to our SEC filings available at sec.gov for a discussion of potential risks and uncertainties.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot